ClinicalTrials.gg
Enrolling by invitationNCT06827535IppocrateUpdated Nov 12, 2026

Long-term Vascular, Functional and Morphological Changes in Glaucoma and Ocular Hypertensive Patients

An observational study in Glaucoma and Ocular Hypertension, sponsored by Mario Stirpe. Enrolling by invitation at 5 sites in Italy. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-12.

Sponsored by Mario Stirpe · Observational

How we know

Updated Nov 12, 20264 sites added4 sites removedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-control
Time perspective
Prospective
Enrollment
400
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 53 studies in Glaucoma with a site in Italy — 7 open to participants now, 8 under way, 1 of them phase 3. Glaucoma · Italy.

Planned enrollment
4th of 13
400 · median 200
Started
2024
with 2 others
Observational
13 of 53
6 open now
Registered
46th of 53
by date

Among the 53 studies in Glaucoma with a site in Italy, this one is the 4th largest by planned enrollment of the 13 observational ones that give a count, is one of 3 that started in 2024, is one of 13 observational ones, and was the 46th registered.

Glaucoma

1,421 studies on the registry are indexed under Glaucoma; 221 are open to participants now.

Browse Glaucoma studies →

Open to participants now

7 of the 53 studies in Glaucoma with a site in Italy are open now. Recruiting first, the newest first:

1 more — sign in →

All 7 open studies →

A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →

Who these studies take

Of the 154 Glaucoma studies recruiting now, 112 (73%) set no upper age limit and 9 (6%) stop at 75 or younger; 13 take children under 18; 44 take healthy volunteers.

This study: 18 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 53 studies in Glaucoma with a site in Italy, or all of them as a file.
02

Study summary

This is an observational study involving patients with glaucoma, those with ocular hypertension and healthy subjects.

The aim of the study is the long term evaluation of functional, vascular and morphological changes in glaucoma and ocular hypertensive patients, compared to healthy subjects, to analyze the temporal relationship of these changes.

Read the detailed description

This is an observational study involving patients with glaucoma, those with ocular hypertension and healthy subjects.

The aim of the study is the long term evaluation of functional, vascular and morphological changes in glaucoma and ocular hypertensive patients, compared to healthy subjects, to analyze the temporal relationship of these changes.

Secondary aims of the study are:

  • evaluating the effect of age on functional, morphological and vascular changes and their relationship,
  • evaluating the effect of myopia on functional, morphological and vascular changes and their relationship,
  • evaluating clinical and demographic factors associated with glaucoma onset and progression,
  • evaluating the effects of vascular, functional and morphological changes on quality of life

During the study patients will undergo BCVA assessment, biomicroscopy, IOP measurement, CCT measurement, gonioscopy, visual field test, optic nerve head and macula OCT scan, OCT angiography scan, fundoscopy, every 6 months (for glaucoma and ocular hypertensive patients) and every 12 months (for healthy subjects). The study lasts 3 years.

Four Italian glaucoma center will partecipate in this study, in addition to the promoter.

Four hundred patients and 100 healthy subjects will be involved.

03

Conditions studied

  • Glaucoma
  • Ocular Hypertension

Keywords

  • glaucoma
  • ocular hypertension
  • vascular changes
  • morphological changes
  • functional changes
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

People attending the hospital

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of primary glaucoma (open or closed angle) or secondary glaucoma (pseudoexfoliative or pigmentary) defined by the presence of a glaucomatous defect of the optic nerve and/or a perimetric glaucomatous defect as defined by the European guidelines
  • Diagnosis of ocular hypertension (defined by the presence of intraocular pressure values≥22 mmHg, optic nerve and visual field examination within normal limits)
  • No Optic nerve disease and IOP\<21mmHg for healthy subjects
  • Age>18 years
  • Able to read and sing the form

Exclusion criteria

Exclusion Criteria:

  1. BCVA \<5/10
  2. Previous eye surgery, except glaucoma surgery or removal of cataracts performed more than 6 months prior to enrollment
  3. Other pathologies that can cause alterations of the optic nerve or visual field defects
  4. Presence of maculopathies
  5. Inability to perform visual field tests
  6. Opacity of the dioptric media such that it is not possible to perform reliable OCT and OCTA of acceptable quality
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Case-control
Time perspective
Prospective
Enrollment
400 participants (estimated)
Patient registry
No

Groups and cohorts

  • Glaucoma

    iagnosis of primary glaucoma (open or closed angle) or secondary glaucoma (pseudoexfoliative or pigmentary) defined by the presence of a glaucomatous defect of the optic nerve and/or a perimetric glaucomatous defect as defined by European guidelines

  • Ocular Hypertension

    Diagnosis of ocular hypertension (defined by the presence of intraocular pressure values ≥22 mmHg, optic nerve and visual field examination within normal limits).

  • Healthy subjects

    No optic nerve disease IOP \< 21 mmHg

06

What researchers measure

Primary outcomes

  1. Rate of disease progression

    Rate of progression of functional, morphological and vascular parameters, calculated on the basis of tests repeated over time

    Time frame: Up to 3 years

Secondary outcomes

  1. Rate of disease progression in relation to age

    Rate of progression of functional, morphological and vascular parameters, in relation to age

    Time frame: Up to 3 years

  2. Rate of disease progression in relation to myopia

    Rate of progression of functional, morphological and vascular parameters, in relation to myopia

    Time frame: Up to 3 years

  3. Rate of disease progression in relation to demographic data

    Rate of progression of functional, morphological and vascular parameters, in relation to clinical and demographic factors collected at baseline (visual acuity, axial length, diagnosis, sex, stage of the disease, etc.)

    Time frame: Up to 3 years

  4. Quality of life in glaucoma and ocular hypertensive patients

    Quality of life questionnaire (National Eye Institute Visual Function Questionnaire-25) scores over time. The minimum value is 0, the maximum value is 100. Higher score means a better outcome.

    Time frame: Up to 3 years

07

Study locations

5 sites
08

References and documents

Publications

  • Sotimehin AE, Ramulu PY. Measuring Disability in Glaucoma. J Glaucoma. 2018 Nov;27(11):939-949. doi: 10.1097/IJG.0000000000001068. PubMed 30161076 ↗
  • Heijl A, Leske MC, Bengtsson B, Hyman L, Bengtsson B, Hussein M; Early Manifest Glaucoma Trial Group. Reduction of intraocular pressure and glaucoma progression: results from the Early Manifest Glaucoma Trial. Arch Ophthalmol. 2002 Oct;120(10):1268-79. doi: 10.1001/archopht.120.10.1268. PubMed 12365904 ↗

Individual participant data

Plan to share: No

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2024 (actual). Primary completion is estimated for Nov 2028, 48 months after the start.

Of 111 non-industry observational studies under Glaucoma, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 208. This study's planned 48 months is close to that.

Counting every sponsor, half of 135 studies reached it within 31 months; a quarter within 11 and three quarters within 208.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 30, 2025
First posted
Feb 14, 2025
StartActual
Nov 14, 2024
Primary completionEst.
Nov 14, 2028
CompletionEst.
Jan 2, 2030
Last update
Nov 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
4 sites added, 4 sites removed
Show 4 added (4 Italy)
  • Ospedale San Paolo - ASST Santi Paolo e Carlo · Milan, Italy
  • Ospedale Maggiore della Carità · Novara, Italy
  • Irccs-Fondazione Gb Bietti · Rome, Italy
  • Azienda Ospedaliera Universitaria di Sassari, Dipartimento di Medicina, Chirurgia e Farmacologia Università di Sassari · Sassari, Italy
Show 4 removed
  • Ospedale San Paolo - ASST Santi Paolo e Carlo · Milan, Italy
  • Ospedale Maggiore della Carità · Novara, Italy
  • Irccs-Fondazione Gb Bietti · Rome, Italy
  • Azienda Ospedaliera Universitaria di Sassari, Dipartimento di Medicina, Chirurgia e Farmacologia Università di Sassari · Sassari, Italy
Nov 12, 2026
Show all 1 update
  1. Nov 12, 2026
    4 sites added, 4 sites removed
    Show 4 added (4 Italy)
    • Ospedale San Paolo - ASST Santi Paolo e Carlo · Milan, Italy
    • Ospedale Maggiore della Carità · Novara, Italy
    • Irccs-Fondazione Gb Bietti · Rome, Italy
    • Azienda Ospedaliera Universitaria di Sassari, Dipartimento di Medicina, Chirurgia e Farmacologia Università di Sassari · Sassari, Italy
    Show 4 removed
    • Ospedale San Paolo - ASST Santi Paolo e Carlo · Milan, Italy
    • Ospedale Maggiore della Carità · Novara, Italy
    • Irccs-Fondazione Gb Bietti · Rome, Italy
    • Azienda Ospedaliera Universitaria di Sassari, Dipartimento di Medicina, Chirurgia e Farmacologia Università di Sassari · Sassari, Italy
    + 2 other changes: verification date and oversight details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06827535
Lead sponsor
Mario Stirpe
Responsible party
Mario Stirpe (Dr, Fondazione G.B. Bietti, IRCCS) — Sponsor-investigator
First posted
Feb 14, 2025
Start date
Nov 14, 2024
Primary completion
Nov 14, 2028 (estimated)
Completion
Jan 2, 2030 (estimated)
Last update
Nov 12, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion